The generation of anti-tumor immunity in the draining lymph nodes is known as the cancer
immunity cycle. Accumulating evidence supports the occurrence of such a cycle at tumor …

The progression of cancer involves a critical step in which malignant cells escape from
control by the immune system. Antineoplastic agents are particularly efficient when they …

Overall survival (OS) benefits of neoadjuvant immunotherapy remain elusive in locally
advanced esophageal squamous cell carcinomas (ESCC). Here, we reported the results of …

Cancer immunogenomics is an emerging field that bridges genomics and immunology. The
establishment of large-scale genomic collaborative efforts along with the development of …

Natural living materials serving as biotherapeutics exhibit great potential for treating various
diseases owing to their immunoactivity, tissue targeting, and other biological activities. In this …

Cell therapy has reached significant milestones in various life-threatening diseases,
including cancer. Cell therapy using fluorescent and radiolabeled chimeric antigen receptor …

Cancer cells undergoing immunogenic cell death (ICD) can initiate adaptive immune
responses against dead cell‐associated antigens, provided that (1) said antigens are not …

The cell surface enzyme CD73 is increasingly appreciated as a pivotal non-redundant
immune checkpoint (IC) in addition to PD-1/PD-L1 and CTLA-4. CD73 produces …

Single-cell and spatial multimodal technologies have propelled discoveries of the solid
tumor microenvironment (TME) molecular features and their correlation with clinical …

Adoptive T cell therapy (ACT) is a fast developing, niche area of immunotherapy (IO), which
is revolutionising the therapeutic landscape of solid tumour oncology, especially metastatic …